Dr. Joe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
701 W 168th St
# Hhsc
New York, NY 10032Phone+1 212-305-6916Fax+1 212-305-6889
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1996 - 1999- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1991 - 1994
Icahn School of Medicine at Mount SinaiClass of 1991
Certifications & Licensure
NY State Medical License 1993 - 2025
Publications & Presentations
PubMed
- 1527 citationsEfficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta
Journal of Clinical Oncology. 2020-01-01 - 572 citationsT-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Acro...Patrick A. Ott, Yung-Jue Bang, Sarina Anne Piha-Paul, Albiruni Ryan Abdul Razak, Jaafar Bennouna
Journal of Clinical Oncology. 2019-02-01 - 1482 citationsPan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapyRazvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy
Science. 2018-10-12
Journal Articles
- Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based ImmunotherapyJonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine
Press Mentions
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival RatesAugust 12th, 2024- Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)April 17th, 2023
- Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory UpdateApril 14th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
